The need for clinical trials in early psychosis
Current treatments for early psychosis are a combination of medication and psychosocial intervention (e.g. therapy and practical support).
However, current medications have a range of undesirable side effects such as sedation, weight gain and impairment of sexual function. Even with the best possible care, some people with early psychosis do not make a full recovery.
In this video Associate Professor James Scott describes the current treatments for early psychosis.
In this video Associate Professor James Scott explores some of the problems with current treatments.
Finally, Associate Professor James Scott describes what kind of treatments patients want.
Australian Early Psychosis Network
Over the last three decades Australian researchers have pioneered new conceptual models related to the identification of those with early psychosis.
Professor Patrick McGorry was named Australian of the Year in 2010 for his efforts to deliver good mental health care to those in the earliest phases of psychosis.
We now need to mirror that sense of innovation with new treatments.
In 2014, the Australian Early Psychosis Network was established to build research and clinical capacity.
The Cadence project hopes to contribute to that initiative.
In this video Professor McGrath explains why the treatment of early psychosis is such a promising area for clinical trials.
Read the 2010 Survey of High Impact Psychosis (SHIP) for a better understanding of the prevalence of psychosis in Australia, and the lives of people living with psychosis.